Because amyloid fibrils are deposited in tissues throughout the body, including the nerves, heart, and GI tract, patients with hATTR amyloidosis can present across a spectrum that includes sensory and motor, autonomic, and cardiac symptoms.1-5
In fact, more than half of patients with hATTR amyloidosis present with a mixed phenotype.6,7
As the disease progresses, symptoms increase in severity, leading to significant disability, decreased quality of life, and untimely death.9,10 hATTR amyloidosis can lead to mortality within 2 to 15 years.2,3,9,11
Due to the variability of the disease, progression of symptoms can also be considerably different from patient to patient.8
References:
We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from the site’s standards you are leaving.
Alnylam assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site's endorsement of Alnylam or this website.
Thank you for visiting our site.